Company profile: Verici Dx
1.1 - Company Overview
Company description
- Provider of RNA signature-based diagnostics for kidney transplant patients, offering pre- and post-transplant prognostic testsβClarava to predict early rejection risk and Tutivia to assess post-transplant rejection riskβand RNA Signature Tests that provide insights into immune response and transplant prognosis, while tracking patient records and the patient journey.
Products and services
- Clarava: A pre-transplant prognostic laboratory test that predicts the risk of early kidney rejection prior to transplantation for kidney patients
- RNA Signature Tests: RNA-based diagnostic tests that utilize RNA signatures to deliver insights into immune response and transplant prognosis for kidney transplant patients
- Tutivia: A post-transplant prognostic test designed to assess the risk of kidney transplant rejection in recipients after surgery
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Verici Dx
Oxford Immunotec
HQ: United Kingdom
Website
- Description: Provider of medical diagnostic tests based on patented T cell measurement technology, including T-SPOT.TB, an interferon gamma release assay for diagnosing latent TB infection and TB disease; T-SPOT.CMV for detecting cytomegalovirus infections; and T-SPOT.PRT for assessing immune responses to various pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Oxford Immunotec company profile β
Organ Transport Systems
HQ: United States
Website
- Description: Provider of portable, hypothermic, oxygenated preservation and transport technology for human organs, offering the LifeCradle HR durable perfusion unit and a complementing single-use organ chamber and fluid circuit kit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Organ Transport Systems company profile β
XVIVO
HQ: Sweden
Website
- Description: Provider of organ perfusion, preservation, and assessment solutions for transplantation, including XPS for ex vivo lung perfusion and assessment; Liver Assist for hypothermic, normothermic, and sub-normothermic liver preservation; Kidney Assist Transport for hypothermic pulsatile perfusion of donor kidneys up to 24 hours; PERFADEX Plus for static cold storage of lungs; STEEN Solution for lung assessment; and XVIVO Academy training.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full XVIVO company profile β
CareDx
HQ: United States
Website
- Description: Provider of transplant care solutions, including non-invasive diagnostics (AlloSure for kidney and AlloMap for heart), remote patient monitoring (AlloHome), pharmacy services managing immunosuppressants and maintenance drugs (The Transplant Pharmacy), and software for organ and cellular transplant program management (Ottr Organ and Ottr Cellular).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full CareDx company profile β
Quell Therapeutics
HQ: United Kingdom
Website
- Description: Provider of engineered regulatory T cell (Treg) therapies for solid organ transplant and autoimmune diseases. Develops QEL-001 to prevent liver transplant rejection without lifelong immunosuppression and, with AstraZeneca, engineered Treg therapies for Type 1 Diabetes and Inflammatory Bowel Disease. Offers a modular platform using proprietary technologies to enhance Tregs, target specific antigens, and direct them to specific body targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Quell Therapeutics company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Verici Dx
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Verici Dx
2.2 - Growth funds investing in similar companies to Verici Dx
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Verici Dx
4.2 - Public trading comparable groups for Verici Dx
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β